Arcus Biosciences Announces New Employment Inducement Grants

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced that the Compensation Committee of the Company's Board of Directors granted one new employee options to purchase a total of 2,850 shares of the Company's common stock at an exercise price per share of $28.72, which was the.

Business Wire • Aug 11, 2026

Arcus Biosciences Q2 Earnings Call Highlights

Arcus Biosciences NYSE: RCUS outlined plans to expand development of its casdatifan cancer program across multiple lines of clear cell renal cell carcinoma, or ccRCC, while reporting second-quarter financial results and updates on its pancreatic cancer and immunology pipelines.

MarketBeat • Aug 9, 2026

Arcus Biosciences, Inc. (RCUS) Q2 2026 Earnings Call Transcript

Arcus Biosciences, Inc. (RCUS) Q2 2026 Earnings Call Transcript

Seeking Alpha • Aug 6, 2026

Arcus Biosciences Reports Second-Quarter 2026 Financial Results and Provides a Pipeline Update

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today reported financial results for the second quarter ended June 30, 2026, and provided a pipeline update on its clinical-stage investigational molecules and discovery programs. "Our recent publication in Nature demonstrated our commitme.

Business Wire • Aug 5, 2026

Arcus Biosciences, Inc. (RCUS) Reports Q2 Loss, Tops Revenue Estimates

Arcus Biosciences, Inc. (RCUS) came out with a quarterly loss of $0.72 per share versus the Zacks Consensus Estimate of a loss of $0.98. This compares to break-even earnings per share a year ago.

Zacks Investment Research • Aug 6, 2026

Kuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law Firm

NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of  Arcus Biosciences, Inc. ( NYSE : RCUS) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.

GlobeNewsWire • Jul 30, 2026

Arcus: 'Buy' On Casdatifan Late-Stage CcRCC Advancement And 1st-Line Expansions

I initiate Arcus Biosciences with a 'Buy' rating, citing late-stage pipeline catalysts and a strong financial runway. The company's lead asset, casdatifan, is advancing in phase 3 PEAK-1 for 2nd-line ccRCC, with enrollment completion expected by the end of 2026. Expansion into 1st-line ccRCC with casdatifan-based TKI-free regimens and multiple upcoming data readouts offers significant upside potential.

Seeking Alpha • Jul 24, 2026

SMMT Shares Updated Ivonescimab Survival Data From NSCLC Study

Summit announces updated HARMONi overall survival data and partners with Arcus to test ivonescimab in kidney cancer, expanding its late-stage development.

Zacks Investment Research • Jul 23, 2026

Arcus Biosciences Announces Clinical Supply Agreement with AVEO Oncology to Evaluate Casdatifan in Combination with Tivozanib for Advanced Kidney Cancer Patients

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced a clinical supply agreement with AVEO Oncology, an LG Chem company (“AVEO”). Under the agreement, the companies will evaluate casdatifan, Arcus's investigational small-molecule HIF-2α inhibitor, in combination with tivozan.

Business Wire • Jul 22, 2026

Arcus Biosciences and Summit Therapeutics Enter Into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer

HAYWARD, Calif. & MIAMI--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, and Summit Therapeutics Inc. (Nasdaq: SMMT), a biopharmaceutical company focused on patient-friendly oncology therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical ne.

Business Wire • Jul 22, 2026